References
- Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7
- Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204
- Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010;206:1-11
- Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014;55:29-36
- Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics—a review. Hum Psychopharmacol 2010;25:281-97
- Montalvo I, Gutierrez-Zotes A, Creus M, et al. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One 2014;9:e89428
- Gonzalez-Blanco L, Greenhalgh AMD, Garcia-Rizo C, et al. Prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res 2016;174:156-60
- Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014;28:421-53
- Pacchiarotti I, Murru A, Kotzalidis GD, et al. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 2015;25:1045-59
- Abosi O, Lopes S, Schmitz S, et al. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig 2018. doi:10.1515/hmbci-2017-0065
- Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry 2011;72(Suppl 1):4-8
- Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 1):9-26
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
- Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009;19:373-82
- Kearns AE, Goff DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425-9
- Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012;15:107-18
- Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52
- Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003;9:344-53